Neurizon Therapeutics Receives Positive Opinion On Orphan Medicinal Product Designation For NUZ-001 In Europe
Amyotrophic Lateral Sclerosis Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulatory and commercial benefits Positions Neurizon to ...
Stockhead on MSN6h
NUZ inks positive opinion on orphan product designation for NUZ-001 in Europe
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...
HotCopper.com on MSN10h
Neurizon's fast-track application for flagship drug in Europe received 'positively'
While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...